EssilorLuxottica gets regulator nod for audio glasses in US, EU for hearing loss
Franco-Italian EssilorLuxottica SA got approval from the Food and Drug Administration to market its over-the-counter audio glasses in the US for people with.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Franco-Italian EssilorLuxottica SA got approval from the Food and Drug Administration to market its over-the-counter audio glasses in the US for people with.
A $549.6 million observatory, situated on a mountaintop in Cerro PachĂłn in Chile, will start operations by October in an attempt to provide.
Global researchers, led by Australiaâs Macquarie University, in a bid to re-engineer life in a laboratory, have completed the worldâs first synthetic yeast.
By Bharti Jayshankar February 1, 2025: A study from the University of Minnesota has revealed a connection between exclusionary discipline (ED) practices in.
HQ Team February 1, 2025: A nine-hour film titled Donât Look Down, released recently, addresses the problem of smartphone addiction among pre-teens and.
Bharti Jayshankar January 31, 2025: A recent meta-analysis published in BMJ Nutrition Prevention & Health reveals that more than 45% of patients with.
Researchers at Cambridge are developing implants that could help repair damaged brain cells and treat diseases like Parkinsonâs.
Vertex Pharmaceuticals Inc.âs non-opioid analgesic to treat moderate to severe acute pain in adults got approval from the US drug regulator.
Britainâs National Health Service will provide a gene therapy that may cure sickle cell disease for patients 12 years and older, according to.
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its ârobust efficacy,â according.